Latest Articles

Publication Date
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada - GlobeNewswire

Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada GlobeNewswire

Published: Oct. 7, 2025, 9:08 p.m.
Endometriosis-associated infertility: Multi-omics insights into pathogenesis and precision therapeutics.

Endometriosis is a prevalent, estrogen-dependent, inflammatory disease that impairs fertility via hormonal dysregulation, immune dysfunction, oxidative stress/ferroptosis, genetic and epigenetic alterations, and microbiome imbalance. We summarize multi-omics insights and clinical …

Published: Oct. 2, 2025, midnight
From biomolecules to breakthroughs: exosomes as next-generation theranostics in female infertility.

Female infertility and reproductive disorders represent a significant global health challenge, with complex etiologies often linked to impaired cellular communication, inflammation, and tissue dysfunction. Exosomes (EXOs), nanosized extracellular vesicles laden …

Published: Oct. 1, 2025, midnight
Reduced Vagal Tone in Women with Adenomyosis.

Adenomyosis is an estrogen-dependent disease featuring chronic inflammation. This study was undertaken to investigate whether the vagal tone is reduced in patients with adenomyosis as compared with healthy women. We …

Published: Sept. 30, 2025, midnight
United States Endometriosis Therapeutics Market Growth Fueled - openPR.com

United States Endometriosis Therapeutics Market Growth Fueled openPR.com

Published: Sept. 29, 2025, 7:26 a.m.
What to expect from Karyopharm Therapeutics Inc. in the next 30 days - Watch List & Stepwise Trade Signal Guides - newser.com

What to expect from Karyopharm Therapeutics Inc. in the next 30 days - Watch List & Stepwise Trade Signal Guides newser.com

Published: Sept. 22, 2025, 7:20 a.m.
EndoCyclic Therapeutics Awarded Rare NIH "Perfect 10" Grant for Endometriosis Therapeutic - BioSpace

EndoCyclic Therapeutics Awarded Rare NIH "Perfect 10" Grant for Endometriosis Therapeutic BioSpace

Published: Sept. 17, 2025, 7:44 a.m.
EndoCyclic Therapeutics Awarded Rare NIH "Perfect 10" Grant for Endometriosis Therapeutic - biospace.com

EndoCyclic Therapeutics Awarded Rare NIH "Perfect 10" Grant for Endometriosis Therapeutic biospace.com

Published: Sept. 17, 2025, 7:44 a.m.
EndoCyclic Therapeutics Awarded Rare NIH "Perfect 10" Grant for Endometriosis Therapeutic - PR Newswire

EndoCyclic Therapeutics Awarded Rare NIH "Perfect 10" Grant for Endometriosis Therapeutic PR Newswire

Published: Sept. 16, 2025, 1 p.m.
M2 Macrophages are Major Mediators of Germline Risk of Endometriosis and Explain Pleiotropy With Comorbid Traits.

Endometriosis is a common gynecologic condition that causes chronic, life-altering symptoms including pain and infertility. There is an urgent need for new non-hormonal targeted therapeutics to treat endometriosis, but until …

Published: Sept. 12, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!